Immunomodulatory Antibody Conjugates for the Treatment of Cancer & Chronic Viral Infections

Time: 2:00 pm
day: day 2 opps
day: Day Two


  • An overview of Silverback’s ImmunoTAC (Immunomodulatory Targeted Antibody Conjugate) technology platform
  • Discussing the discovery and development of ImmunoTAC molecules containing a TLR8 agonist payload designed to stimulate local activation of myeloid cells
  • Examining how broad and versatile potential of the ImmunoTAC platform is exemplified by oncology (SBT6050 and SBT6290) and virology (SBT8230) development candidates